<DOC>
	<DOC>NCT00759226</DOC>
	<brief_summary>This multicenter open labeled phase 2 trial examines the efficacy of a combination of Gemcitabine 1000 mg/m2 (30 min), Cisplatin 30 mg/m2 (90 min), Folinic Acid 200 mg/m2 (30 min) and 5-FU 750 mg/m2 (24h CI) all given day 1,8 q D22 in patients with inoperable esophageal cancer. The combination was considered to be suitable for further evaluation with a freedom of progression rate (PR+CR+SD) of more than 60% and not be be of further interest with a rate of less than 40%. Given an alpha error of 5% and an beta error of 10% at least 66 evaluable patients were needed based on a 2-Stage Simon design with a first evaluation after 25 evaluable patients.</brief_summary>
	<brief_title>Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Age&gt;=18 Histologically proven inoperable esophageal cancer Karnofsky Performance status &gt;=60% Estimated life expectancy of &gt; 12 weeks Measurable disease No other oncologic therapy Measurable disease Adequate bone marrow function Geographic proximity and compliance Informed consent Negative pregnancy test and adequate contraception Insufficient hepatic or renal function Elevated serum calcium Pregnancy/breast feeding Active infection Other malignancies Systemic tumour complications requiring emergency interventions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>5-FU</keyword>
	<keyword>Folinic Acid</keyword>
	<keyword>inoperable esophageal cancer</keyword>
</DOC>